{"cdcTestId":"2022-0075","testcaseName":"Patient is administered second dose of Pfizer Covid-19 Vaccine at 21 - 4 days","vaccineGroup":"COVID-19","evaluationTestType":"All Valid: Forecast Test","forecastTestType":"Recommended based on interval","assessmentDate":"2022-10-19T00:00:00","patient":{"dob":"1999-10-02T00:00:00","gender":"M"},"evaluation":{"seriesStatus":"Not complete","administeredDoses":[{"dateAdministered":"2022-10-02T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-10-19T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null}]},"forecast":{"forecastNum":"3","earliestDate":"2022-12-14T00:00:00","recommendedDate":"2022-12-14T00:00:00","pastDueDate":"0001-01-01T00:00:00"},"doses":[{"dateAdministered":"2022-10-02T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-10-19T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null}],"dateAdded":"2020-10-06T20:00:00","dateUpdated":"2022-09-27T11:50:36.268","generalDescription":"This test case describes when a patient is administered the second dose of the Pfizer Covid-19 vaccine at 21 - 4 days after the first dose, that the dose is valid. A booster dose should be forecasted.","changedInVersion":"4.27","reasonForChange":"v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022). \nv4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that all persons aged 12 and older should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of the primary series (01/06/2022).\nv4.16 Updated the Forecast Recommended Date based on Clinical Considerations Information (11/29/21), that states all persons aged 18 years and older should received a booster dose of Covid-19 vaccine.\nv4.15 Updated per ACIP Recommendation on 11/19/2021, where individuals 18 years and older may receive a booster dose.\nv4.12 Updated per ACIP recommendations, on 09/22/2021, for Pfizer Covid-19 booster dose for individuals 65 years and older."}